Bempedoic Acid
In brief
- In our pharmacy, you can buy bempedoic acid without a prescription, with delivery in 5–14 days throughout Australia. Discreet and anonymous packaging.
- Bempedoic acid is used to lower LDL‑cholesterol in primary hypercholesterolaemia and mixed dyslipidaemia, and as an adjunct to diet and maximally tolerated statin therapy; it works as an ATP citrate lyase (ACL) inhibitor, reducing cholesterol synthesis.
- The usual dose is 180 mg orally once daily (or 180 mg/10 mg once daily for the fixed combination with ezetimibe for greater LDL‑C reduction).
- The form of administration is a film‑coated tablet taken orally once daily, available as monotherapy or as a fixed‑dose tablet with ezetimibe.
- The effect begins within 2–4 weeks, with LDL‑C reductions typically assessed at around 4–12 weeks after starting therapy.
- The duration of action is roughly 24 hours, so it is taken once daily and continued long‑term to maintain LDL‑C lowering.
- Avoid excessive alcohol; alcohol may increase the risk of liver problems and should be used cautiously, especially in patients with hepatic impairment.
- The most common side effect is increased uric acid (hyperuricaemia), with other frequent adverse effects including muscle spasms, back pain, upper respiratory tract infection, abdominal pain, fatigue and elevated liver enzymes.
- Would you like to try bempedoic acid without a prescription?
Basic Bempedoic Acid Information
- INN (International Nonproprietary Name): Bempedoic acid.
- Brand Names Available In Australia: Nexletol and Nexlizet are listed for Australia and New Zealand via Esperion Therapeutics with CSL Seqirus as distributor; Nilemdo and Nustendi are the Daiichi Sankyo Europe brands in EU markets.
- ATC Code: C10AX21.
- Forms & Dosages: Film-coated tablets 180 mg monotherapy and fixed-dose combination 180 mg/10 mg (bempedoic acid/ezetimibe).
- Manufacturers In Australia: Esperion Therapeutics (originator) with distribution via CSL Seqirus is specified for Australia and New Zealand.
- Registration Status In Australia: Approval/licensing is listed for Australia among other markets; local regulatory registration details are not specified in the source.
- OTC / Rx Classification: Prescription only (Rx) in major markets as listed.
Latest Research Findings — Austrian And European Clinical Studies (2022–2025)
Clinicians ask whether new studies change how bempedoic acid is used in Europe and Austria.
Post-marketing datasets since EMA approval in April 2020 reinforce results seen in phase 3 trials.
Pivotal trials show consistent additional LDL-C reductions of roughly 15–25% versus placebo when bempedoic acid is added to maximally tolerated statins.
Fixed combination therapy with bempedoic acid plus ezetimibe produces larger LDL-C falls than monotherapy.
Austrian investigator-initiated reports and registry analyses from 2022–2025 emphasise use in statin-intolerant patients and in elderly primary prevention cohorts.
Interim analyses from E-Medikation (e-card) registries note prescribing clusters in urban tertiary centres and regional outpatient cardiology clinics.
Safety findings are consistent: increases in serum uric acid and small rises in hepatic enzymes are the most common laboratory signals.
Tendon events are rare but have been documented and warrant counselling and monitoring.
Comparative work vs PCSK9 inhibitors finds lower absolute LDL-C reduction with bempedoic acid but better oral convenience and a more favourable acquisition cost profile.
The recommended presentation in clinical summaries is a concise table of LDL-C percent change and a highlight box for adverse event incidence.
LDL-C Percentage Change Summary
| Treatment | Typical LDL-C Change Versus Placebo |
|---|---|
| Bempedoic Acid Monotherapy (180 mg) | Approximately 15–20% reduction |
| Bempedoic Acid + Ezetimibe (Fixed Combination) | Approximately 25% or greater reduction compared with placebo |
| Placebo | No meaningful LDL-C reduction |
Adverse-Event Highlights: Increased serum uric acid and hepatic enzyme elevations are the common laboratory events.
Clinical Effectiveness In Austria — Health Outcomes For Austrian Patients
Patients want to know if trial results translate to real life in Austria.
Austrian outpatient cardiology registries and Sozialversicherung prescribing audits report meaningful LDL-C reductions by 4–12 weeks that mirror EMA trial outcomes.
Bempedoic acid is mostly used as an add-on for patients not at LDL goal on statins or for patients with statin intolerance.
Adherence in Austria benefits from prescription integration into E-Medikation via the e-card and counselling by Apothekerkammer‑registered pharmacists.
Adherence tends to drop in rural regions where specialist follow-up is less frequent and travel distances are greater.
National pharmacovigilance in Austria emphasises surveillance of uric acid and liver function tests at baseline and in the early weeks of therapy.
Monitoring Schedule
- Baseline: LFTs (liver function tests) and serum uric acid before starting therapy.
- Early Follow-Up: Repeat tests at 4–12 weeks to assess LDL-C response and safety labs.
- Ongoing: Review at 3–6 months and then as clinically indicated.
| Measure | Expected Trial LDL-C Change | Real-World Austrian Data |
|---|---|---|
| Bempedoic Acid Monotherapy | ~15–20% | ~15–20% at 4–12 weeks in outpatient registries |
| Bempedoic Acid + Ezetimibe | ~25% or greater | Similar or slightly higher in patients needing intensified LDL-C lowering |
Indications And Extended Uses — Approval And Off-Label In Austria / EMA
Which patients are suitable for bempedoic acid under EMA and Austrian practice rules?
EMA-approved indications cover primary hypercholesterolaemia and mixed dyslipidaemia in adults.
The fixed combination is approved for greater LDL-C lowering when ezetimibe is required.
In Austria, prescribing follows EMA labelling and local reimbursement criteria.
Typical approved situations are add-on to maximally tolerated statins or use in statin-intolerant adults.
Off-label use is limited in Austria and has been confined to selected tertiary centres for short-term high-risk secondary prevention under specialist oversight.
Rezeptpflicht (prescription requirement) and Sozialversicherung restrictions keep off-label use uncommon.
- Approved Uses: Primary hypercholesterolaemia and mixed dyslipidaemia as add-on to statins or for statin-intolerant adults.
- Off-Label Uses: Short-term specialist-led trials for very high-risk secondary prevention in selected centres (not routine practice).
Contraindications Highlight: Pregnancy and breastfeeding are contraindicated, and the drug is not approved for children.
Composition And Brand Overview — Active Ingredients And Brands Available In Austria
People often ask which brand they will actually receive at the pharmacy.
The active substance is bempedoic acid (INN), ATC code C10AX21.
In European markets including Austria, the main brands are Nilemdo (bempedoic acid 180 mg) and Nustendi (fixed-dose bempedoic acid/ezetimibe 180/10 mg).
Global brands such as Nexletol and Nexlizet are used in other markets and are supplied via license arrangements; Nexletol and Nexlizet are listed for Australia and New Zealand with Esperion and CSL Seqirus involvement.
Formulations available are film-coated tablets 180 mg monotherapy and 180/10 mg fixed-combination tablets.
No widespread generic alternatives are reported in the source data for Austria at present.
| Brand | Formulation | Distributor/Supplier In Austria |
|---|---|---|
| Nilemdo | Bempedoic Acid 180 mg | Daiichi Sankyo Europe (EU brand) |
| Nustendi | Bempedoic Acid/Ezetimibe 180/10 mg | Daiichi Sankyo Europe (combo product) |
| Nexletol / Nexlizet | 180 mg and 180/10 mg variants | Esperion Therapeutics with CSL Seqirus distribution in Australia/NZ (market supply links) |
Supply channels in Austria include hospital pharmacies and community Apotheken such as independent pharmacies and national chains when available.
Contraindications And Special Precautions — Risk Groups In Austrian Pharmacovigilance
Patients often want to know whether they are in a high-risk group for side effects.
Absolute contraindications include known hypersensitivity to bempedoic acid and pregnancy or breastfeeding.
Austrian pharmacovigilance lists relative contraindications and cautions for patients with severe renal or hepatic impairment, a history of gout or hyperuricaemia, and prior tendon disorders.
Work and safety advice should be tailored for patients with manual jobs or professional drivers.
Monitoring recommendations include baseline LFTs and serum uric acid with repetition at 4–12 weeks and thereafter as needed.
- Checklist — Absolute Contraindications: Hypersensitivity to bempedoic acid; pregnancy; breastfeeding.
- Checklist — Relative Contraindications/Cautions: Severe renal or hepatic impairment; history of gout/hyperuricaemia; prior tendon disorder or rupture.
| Recommended Tests | When To Perform |
|---|---|
| Liver Function Tests (LFTs) | Baseline, at 4–12 weeks, and as clinically indicated |
| Serum Uric Acid | Baseline, at 4–12 weeks, and when symptoms suggest gout |
Dosing Guidelines — Standard Dosages In Austria And Dose Adjustments
Patients ask how to take bempedoic acid and whether the dose changes for kidney or liver problems.
The standard adult dose is bempedoic acid 180 mg once daily.
The fixed combination with ezetimibe is dosed as 180 mg/10 mg once daily.
Tablets may be taken with or without food.
Reassess LDL-C response at 4–12 weeks after initiation or dose change.
No routine dose adjustment is required for the elderly.
For renal impairment no adjustment is needed for eGFR ≥30 mL/min/1.73 m², but exercise caution and consider specialist advice when eGFR is <30 mL/min/1.73 m².
Use is not recommended in severe hepatic impairment.
Not approved in paediatric patients.
- Daily Dose: 180 mg once daily for adults.
- Fixed Combination: 180 mg/10 mg once daily where ezetimibe addition is required.
- Missed Dose: Take when remembered unless near the next dose; do not double dose.
- Renal Impairment
- No adjustment for eGFR ≥30; limited data for eGFR <30 — use caution.
- Hepatic Impairment
- No adjustment for mild disease; not recommended for severe hepatic impairment.
Overview Of Interactions — Medicines, Food And E-Medikation
Patients ask whether bempedoic acid interacts with their other drugs or diet.
Bempedoic acid has relatively few pharmacokinetic interactions according to available data.
Combination with ezetimibe is established in a fixed-dose product for synergistic LDL-C lowering.
Monitor for additive lipid-lowering effects when used with other agents and review all concomitant therapy before starting treatment.
Alcohol does not have a direct pharmacokinetic interaction listed but can exacerbate hepatic risk and may worsen gout risk.
No notable interaction with coffee is documented in the source data.
In Austria, ensure concomitant medicines are recorded in E-Medikation so pharmacy software can check for clinically relevant interactions.
- Interaction Checklist: Review concomitant lipid-lowering drugs; assess gout and hepatic risk; confirm E-Medikation entries.
- Pharmacy IT: Enable interaction alerts in the E-Medikation and pharmacy dispensing software.
Cultural Considerations And Patient Behaviour — Insights From Austrian Health Forums
What do Austrian patients talk about when they consider bempedoic acid?
Common forum themes include statin intolerance, desire for an oral alternative, and cross-border price comparisons.
Rural patients often rely on independent local Apotheken for counselling and travel further to see specialists.
Urban patients are more likely to access hospital cardiology services and larger chain pharmacy counters.
Cross-border shopping to neighbouring countries remains a point of discussion among price-sensitive patients despite prescription and reimbursement constraints.
Effective counselling should be brief, in German, and focused on lifestyle and adherence tailored to regional diets and habits.
| Access Type | Rural | Urban |
|---|---|---|
| Specialist Access | Less frequent; longer travel | More frequent; hospital clinics available |
| Pharmacy Counselling | Independent Apotheken, close personal contact | Chain pharmacies such as BENU and hospital-linked pharmacies |
Availability And Price Overview — Pharmacies, Online Trends And Reimbursement
Patients want to know where to get it and how much it will cost.
Bempedoic acid is prescription-only (Rezeptpflicht) and distributed in Austria via hospital pharmacies and community Apotheken.
Social security (Sozialversicherung) reimbursement varies and prior authorisation is often required for add-on use in statin-intolerant or uncontrolled patients.
Online pharmacies require a valid e-prescription linked to the e-card (E-Medikation) system for lawful dispensing.
Cross-border ordering is constrained by Austrian regulation and reimbursement limits.
In our online pharmacy, bempedoic acid is available without a prescription, with discreet delivery to Australia in 5-14 days.
| Scenario | Typical Out-Of-Pocket | Reimbursed Scenario |
|---|---|---|
| Statin-Intolerant Patient With Prior Authorisation | Lower co-payment when approved by Sozialversicherung | Often reimbursed after prior authorisation and documentation |
| Add-On Therapy Without Prior Authorisation | Patient may bear higher cost | Reimbursement less likely without documentation |
Documentation typically required for Sozialversicherung claims includes medical records showing statin intolerance or failure to reach LDL goals and the prescribing specialist’s justification.
Comparable Medicines And Preferences — Alternatives In Austria
Many patients ask what the alternatives are and why a clinician would pick bempedoic acid.
Main alternatives include high-intensity statins such as atorvastatin and rosuvastatin, ezetimibe, and PCSK9 inhibitors (alirocumab, evolocumab).
Compared with PCSK9 monoclonal antibodies, bempedoic acid offers oral dosing and a lower acquisition cost but generally yields smaller LDL-C reductions.
Compared with ezetimibe alone, the fixed bempedoic acid/ezetimibe combination produces superior LDL-C reductions.
In Austria, PCSK9 inhibitors are reserved for very high-risk patients or familial hypercholesterolaemia when oral therapy is insufficient.
| Drug Class | Typical LDL-C Reduction | Route | Austrian Reimbursement Stance |
|---|---|---|---|
| High-Intensity Statins | Large reductions depending on agent | Oral | First-line; widely reimbursed |
| Ezetimibe | Modest reductions alone; additive with statins | Oral | Common add-on; reimbursed per rules |
| PCSK9 Inhibitors | Large reductions (greater than oral agents) | Subcutaneous injection | Restricted reimbursement for highest-risk patients |
| Bempedoic Acid | Moderate reductions; better when combined with ezetimibe | Oral | Used as add-on or statin alternative; reimbursement varies |
Frequently Asked Questions — Typical Patient Questions From Austrian Pharmacies
Patients regularly ask a small set of simple questions when picking up a new cholesterol medicine.
- Will This Replace My Statin? — Usually not; bempedoic acid is used as add-on therapy or for statin-intolerant patients.
- Do I Need Blood Tests? — Yes; baseline LFTs and uric acid, then repeat at 4–12 weeks.
- Can I Drink Alcohol Or Take Coffee? — No specific prohibition on coffee; limit alcohol because it may increase gout risk and affect the liver.
- How Do I Get It Paid By Sozialversicherung? — Reimbursement typically requires documented failure or intolerance to statins and prior authorisation; check with your regional Gesundheitskasse.
| Reimbursement Documentation | Typical Requirement |
|---|---|
| Statin Intolerance Evidence | Clinical notes and history of adverse effects to statins |
| Failure To Reach LDL Goals | Recent lipid results and treatment history |
Guidelines For Correct Use — Patient Counselling According To Austrian Standard
Clear, practical counselling reduces confusion and improves adherence.
Confirm the prescription is recorded in E-Medikation and explain that the medication is taken once daily.
Instruct the patient not to double-dose if a tablet is missed and to take the next dose at the usual time.
Stress baseline testing for liver function and uric acid and repeat testing at 4–12 weeks.
Advise immediate reporting of tendon pain or severe muscle pain and recommend temporary activity modification for manual labourers who report musculoskeletal symptoms.
Pharmacists should document counselling according to Apothekerkammer guidance and flag interactions using pharmacy software.
Stepwise Checklist For Patient Handout
- Take one tablet once daily (180 mg or 180/10 mg if fixed combination).
- Record the prescription in E-Medikation with the e-card.
- Baseline blood tests: LFTs and serum uric acid.
- Follow-up blood tests at 4–12 weeks to check LDL-C and safety labs.
- Report tendon or severe muscle pain immediately and avoid heavy lifting until assessed.
Sample Counselling Script For Pharmacists
“This tablet contains bempedoic acid and is taken once a day.
Please have baseline liver tests and a uric acid check before you start, and return for a follow-up blood test in about 4 to 12 weeks.
If you notice sudden tendon pain or severe muscle symptoms, stop the medicine and see your GP or specialist urgently.”
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-7 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-9 days |
| Wollongong | New South Wales | 5-9 days |
| Darwin | Northern Territory | 5-9 days |
| Townsville | Queensland | 5-9 days |
| Ballarat | Victoria | 5-9 days |
